Latest Distributions News

CD Private Equity Fund II has announced a special unfranked dividend of AUD 0.09 per ordinary unit, payable on February 24, 2025, signaling steady returns for investors.

Biome Australia Limited has expanded its distribution footprint to over 6,000 health retail and practitioner locations, marking a 20% increase in six months and advancing toward its Vision 27 target of 8,000 sites by FY27.

Bioxyne Limited has raised its FY2025 revenue forecast to $25 million, driven by a remarkable 267% increase in first-half revenue and strong momentum from its subsidiary Breathe Life Sciences.

Memphasys Limited marks a pivotal quarter with the completion of clinical trials for its Felix™ System, strategic market expansions in Greater China and the Middle East, and a successful capital raise to fuel growth.

Universal Biosensors has secured a Vendor Master Purchase Agreement with Chewy and launched its Petrackr veterinary glucose monitoring system on Amazon, positioning itself for significant growth in North America's online pet care market.

KKR Credit Income Fund has announced an estimated monthly distribution of AUD 0.0167 per ordinary unit, primarily as a return of capital, with payment scheduled for mid-February.

Hydrix Limited has extended its contract with Paul Hartmann AG, adding $2.8 million in revenue and reinforcing its international growth strategy.

Gryphon Capital Income Trust has announced an estimated ordinary dividend of AUD 0.0141 per unit for January 2025, payable in February. The distribution is unfranked and reflects the trust's ongoing income strategy.

EZZ Life Science Holdings delivered a robust Q2 FY25 with a 16.6% increase in customer receipts and a 308% jump in operating cash flows, while gearing up for US market entry and expanding its global footprint.

Regal Investment Fund has updated its dividend announcement, confirming an actual ordinary dividend of AUD 0.10 per unit payable in March 2025. The distribution relates to the six-month period ending December 31, 2024.

Forbidden Foods Limited has more than doubled its group revenues in Q2 FY25 following the acquisition of Oat Milk Goodness, driven by expanded retail distribution and strong ecommerce growth.

Firebrick Pharma has made notable progress expanding its Nasodine nasal spray in Singapore, securing major distribution and marketing agreements that set the stage for retail sales growth in 2025.